Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early PSMA PET change and response to first-line systemic therapy in metastatic clear cell renal cell carcinoma
2024-517098-26-00Phase 2Authorised
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Mar 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium ga-68 gozetotide in clear cell renal cell carcinoma (ccRCC), sponsored by Cliniques universitaires Saint-Luc. Planned start Mar 2025; status: authorised.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2024-517098-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517098-26-00.